Epstein-Barr virus infection
MONDO:0005111An infection that is caused by Epstein-Barr virus.
Also known as: EBV infection, Epstein-Barr Virus infection, Human gammaherpesvirus 4 caused disease or disorder, Human gammaherpesvirus 4 disease or disorder, Human gammaherpesvirus 4 infectious disease, EBV infections, Epstein Barr Virus infections, Herpesvirus 4 infections, Human
77 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New mRNA vaccine targets Epstein-Barr virus in first human trial
⭐️ VACCINE ⭐️ Not yet recruitingThis early-stage trial is testing a new mRNA vaccine called VXCO-102 against Epstein-Barr virus (EBV) in 45 healthy adults aged 18 to 25. The main goal is to check if the vaccine is safe and triggers an immune response. EBV is a common virus that can cause mononucleosis and is li…
Phase: PHASE1 • Sponsor: Vaccine Company, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:25 UTC
-
Immunotherapy combo may outperform chemo in rare lymphoma
Disease control Not yet recruitingThis Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…
Phase: PHASE3 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Which antibiotic combo is safer for your kidneys? new trial aims to find out
Disease control Not yet recruitingThis study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…
Phase: PHASE4 • Sponsor: Bassett Healthcare • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody shows promise against Post-Transplant virus threat
Disease control Not yet recruitingThis phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to b…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a cancer drug stop a deadly complication in transplant patients?
Prevention Not yet recruitingThis study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will en…
Phase: PHASE1 • Sponsor: Jennifer Amengual • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Donor t cells aim to block virus after transplant
Prevention Not yet recruitingThis early-stage study tests whether specially prepared immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for side effects and infection. …
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
New drug aims to stop EBV in kidney transplants
Prevention Not yet recruitingThis study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant recipients who have never had EBV but receive a kidney from an EBV-positive donor. Nine participants will receive either the drug or a placebo for 28 days, along…
Phase: PHASE2 • Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Jun 27, 2026 08:14 UTC
-
Worldwide ICU infection snapshot aims to save lives
Knowledge-focused Not yet recruitingThis observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…
Sponsor: Universidad de la Sabana • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
23,000 seniors join study to unlock secrets of aging and infection
Knowledge-focused Not yet recruitingThis research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
30,000 blood samples could revolutionize rapid disease testing
Knowledge-focused Not yet recruitingThis study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…
Sponsor: LumiraDx UK Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Can the Body's own 'Off Switch' for inflammation predict who survives severe infection?
Knowledge-focused Not yet recruitingThis study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…
Sponsor: Second Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC